Drugs / Estriol
Estriol
also known as
(17 beta)-estra-1,3,5 (10)-trien-3,17-diol · Blissel · Blissel (estriol) · Estriol ( E3) · Gelistrol (estriol) · ITFE-2026 · Oekolp forte · Vaginal estriol ( E3)
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03343912 | Nov 2017 → Jan 2018 | pregnancy disorder | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 1 | NCT03363997 | Sep → Dec 2016 | — | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 1 | NCT01370551 | Apr 2011 → Jul 2012 | postmenopausal atrophic vaginitis | Medinova AG | Completed | No outcome recorded |
| Phase 1 | NCT00908570 | Jun 2009 → Mar 2011 | vaginal disorder | Gynuity Health Projects | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT02967510 | Oct 2016 → May 2018 | postmenopausal atrophic vaginitis | ITF Research Pharma, S.L.U. | Completed | Mixed |
| Phase 2 | NCT02413008 | Oct 2015 → Feb 2017 | postmenopausal atrophic vaginitis | ITF Research Pharma, S.L.U. | Completed | No outcome recorded |
| Phase 2 | NCT01466114 | Oct 2011 → Dec 2021 | primary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis | University of California, Los Angeles | Unknown | No outcome recorded |
| Phase 2 | NCT00866437 | Apr 2009 → May 2010 | premenstrual tension | EVE Medical Systems Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT00302731 | Feb 2006 → Jan 2014 | premature menopause | Jeanne Drisko, MD, CNS, FACN | Terminated | No outcome recorded |
| Phase 2 | NCT02033512 | Jan 2003 → Jan 2004 | — | University Potiguar | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03774407 | Jun 2019 → Nov 2020 | multiple sclerosis | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT06391372 | Apr 2024 → Mar 2025 overdue | pelvic organ prolapse, postmenopausal atrophic vaginitis | Hatice Tukenmez Kurnaz | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02419729 | Mar → Oct 2015 | postmenopausal atrophic vaginitis | Faculdade de Medicina do ABC | Completed | No outcome recorded |
| Phase 3 | NCT04574999 | Jan 2008 → Feb 2009 | postmenopausal atrophic vaginitis | Italfarmaco S.A | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT06633705 | Nov 2023 → Jul 2024 | — | Koc University Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07344064 | Feb → Jul 2026 overdue | bacterial vaginosis | Queen Savang Vadhana Memorial Hospital, Thailand | Not yet recruiting | No outcome recorded |
| — | NCT04735549 | Sep 2021 → Oct 2023 | postmenopausal atrophic vaginitis | MeLSyTech, Ltd | Completed | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 1 | NCT03116022 Comparator | Jun 2017 → Dec 2018 | sexual disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 1 | NCT02733731 Comparator | Feb → May 2016 | postmenopausal atrophic vaginitis | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04159493 Comparator | Jun 2021 → Feb 2023 | postmenopausal atrophic vaginitis | Aspen USA Inc | Withdrawn | No outcome recorded |
| Phase 2 | NCT04487392 Comparator | Dec 2020 → Sep 2021 | postmenopausal atrophic vaginitis | University of Nove de Julho | Withdrawn | No outcome recorded |
| Phase 2 | NCT01408030 Comparator | Aug 2011 → Sep 2014 | hereditary hemorrhagic telangiectasia | James Gossage | Completed | No outcome recorded |
| Phase 2 | NCT00873262 Comparator | Apr 2009 → May 2010 | premenstrual tension | EVE Medical Systems Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT00451204 Comparator | Mar 2007 → Jul 2014 | relapsing-remitting multiple sclerosis | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00816556 Comparator | Oct 2008 → Sep 2011 | postmenopausal atrophic vaginitis | Maire Mac Bride | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT06425978 Comparator | May 2024 → Mar 2026 | — | Fundacion Dexeus | Completed | No outcome recorded |
| Phase 4 | NCT02906111 Comparator | Nov 2016 → Jun 2017 | prolapse of female genital organ | Salvatore Caruso | Unknown | No outcome recorded |
| Phase 4 | NCT03044652 Comparator | Nov 2016 → Jun 2017 | postmenopausal atrophic vaginitis | Dr. August Wolff GmbH & Co. KG Arzneimittel | Completed | No outcome recorded |
| Phase 4 | NCT03032848 Comparator | Nov 2013 → Dec 2016 | endometrial disorder, pelvic organ prolapse, postmenopausal atrophic vaginitis | Federal University of Paraná | Completed | No outcome recorded |
| — | NCT06873971 Comparator | Dec 2025 → Nov 2026 expected | — | University of Nove de Julho | Recruiting | No outcome recorded |
| — | NCT07854873 Comparator | Oct 2022 → Jan 2026 | female stress incontinence, pelvic organ prolapse | Poznan University of Medical Sciences | Completed | No outcome recorded |
| — | NCT05335317 Comparator | Apr 2022 → Sep 2025 overdue | postmenopausal atrophic vaginitis, prolapse of female genital organ | MeLSyTech, Ltd | Recruiting | No outcome recorded |
| — | NCT04045379 Comparator | Aug 2019 → Aug 2025 overdue | postmenopausal atrophic vaginitis | Federal University of São Paulo | Active not recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Estriol | “The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks,...” NCT04487392 ↗32“In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and...” NCT02033512 ↗ “Gynoflor® vaginal tablets (containing Lactobacillus acidophilus KS400 and 0.03 mg estriol)” NCT07344064 ↗ “Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L” NCT00873262 ↗ “Vaginal Cream that contains estriol (1mg estriol in 1 g cream)” NCT06633705 ↗ “Topical estrogen cream treatment: Estriol 1mg daily.” NCT02419729 ↗ “4. Estriol 3mmol/l” NCT00866437 ↗ |
| Known as | (17 beta)-estra-1,3,5 (10)-trien-3,17-diol | “Estriol suppository ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol).” NCT05335317 ↗ |
| Known as | Blissel | “Blissel®, Estriol vaginal gel 50 micrograms/g” NCT06425978 ↗ |
| Known as | Blissel (estriol) | “Blissel (estriol)” NCT02413008 ↗ |
| Known as | Estriol ( E3) | “Estriol ( E3)” NCT06873971 ↗ |
| Known as | Gelistrol (estriol) | “Gelistrol (estriol)” NCT02413008 ↗ |
| Known as | ITFE-2026 | “new low-concentration estriol formulation (ITFE-2026 0.005%)” NCT04574999 ↗ |
| Known as | Oekolp forte | “Vaginal estriol (Oekolp forte) was administered once daily for 14 days, followed by twice-weekly administration for 8 weeks before urogynecological surgery.” NCT07854873 ↗ |
| Known as | Vaginal estriol ( E3) | “Vaginal estriol ( E3)” NCT06873971 ↗ |
| Route | Oral | “estradiol .5mg, estriol 2.0mg, progesterone 100mg dosed orally / day” NCT00302731 ↗ |